XFOR vs ERH Comparison

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company's investment portfolio includes direct debt instruments, which are interests in amounts owed to lenders by corporate or other borrowers. It also invests in various industries which includes auto components, hotels, household durables, media, specialty retail, apparel, oil, gas, consumable fuels, industrials, information technology, telecommunication services, financial and healthcare. Its investment advisor is Wells Fargo Funds Management LLC.